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Abstract
Objectives: To estimate the lifetime prevalence of four sexually transmitted infections (STIs) and
to identify correlates of these infections among patients seeking care for a substance use disorder at
a specialized DeAddictions unit in southern India.
Methods: Consecutive inpatients (n = 361; 97% male; M age = 36.7 years) admitted to DeAddictions
Unit of the National Institute of Mental Health and Neuro Sciences in Bangalore, India, participated
in a structured interview to obtain demographic, psychiatric, sexual behavior, and substance use data;
and provided a blood sample for serologic testing for HIV, chlamydia, syphilis, and Hepatitis B.
Results: One-quarter of all patients tested positive for at least one STI. Lifetime seroprevalence rates
were 12.9% for syphilis, 10.3% for chlamydia, 3.1% for Hepatitis B, and 1.1% for HIV. Analyses
did not reveal any consistent pattern of associations between STI status and sociodemographic,
psychiatric, and sexual behavioral characteristics.
Conclusions: All patients should receive a comprehensive sexual assessment during standard care;
for those patients who report risky sexual practices, we recommend voluntary counseling and
serologic testing for STIs. Although we do not recommend universal testing for STIs at this time,
this should be revisited based upon national epidemiologic surveillance data.
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1. Introduction
Persons experiencing alcohol and other drug addictions appear to be more likely than non-
addicted persons to be infected with a sexually transmitted infection (STI). For example, Cook
et al. (2002) recruited 240 sexually active adolescents from clinical and community settings
and found that the prevalence of herpes simplex virus-2 infections was higher among females
with an alcohol use disorder (AUD; 19%), compared to those without an AUD (10%) (adjusted
odds ratio = 8.1). Cook and Clark (2005) conducted a systematic review of published literature
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on the association between problematic alcohol consumption and STIs, and reported that 8 of
11 studies found a significant association between alcohol consumption and at least one STI.
Evidence regarding the association between HIV and drug abuse can also be found (Aceijas
et al., 2004). Much of this evidence comes from patients who have engaged in sharing of
injection needles and other drug use paraphernalia. Fewer studies have examined the
relationship between HIV (and other STIs) and abuse of non-injectable drugs, but several
studies also suggest an increased vulnerability to HIV and other STIs among persons who use
non-injectable drugs (Bachmann et al., 2000, Poulin et al., 1999, Shoptaw et al., 2003). At least
one study has not found an increased risk of STIs (Liebschutz et al., 2003), so additional
research is needed.
Given associations between STIs and alcohol / drug abuse in developed countries, it is plausible
that such associations may also exist in developing countries. One developing country that has
been identified as the next possible global epicenter for HIV is India. India may already have
the greatest number of HIV infections (5.1 million) of any country in the world (Solomon et
al., 2004, Godbole and Mehendale, 2005, UNAIDS, 2004). Because India has the world's
second largest population (and is projected to have the world's largest population by the year
2050), some fear that India may become a major epicenter of the HIV pandemic. Globally,
HIV is the second leading cause of disability-adjusted life years, an indicator of the burden of
disease (Michaud et al., 2001).
In addition to HIV, several other STIs are believed to be prevalent in India. Surveillance data
are sparse, however, due to recent recognition of STIs as a major public health problem, stigma
and discrimination associated with the STIs, and limited availability of diagnostic facilities
and other resources (Desai et al., 2003). Moreover, the presence of STIs increases the risk of
HIV infection (Wasserheit, 1992). Thus, in formation regarding the prevalence of HIV and
other STIs is essential to effective HIV and STI control and prevention in India (Risbud,
2005).
To our knowledge, no research has examined whether persons in treatment for alcohol and
drug addiction in India are at elevated risk for infection with HIV and other STIs (Godbole and
Mehendale, 2005). Therefore, the primary purpose of this study was to estimate the lifetime
prevalence of four STIs (viz., HIV, chlamydia, syphilis, hepatitis B) among both men and
women seeking treatment for a substance use disorder at a specialized DeAddictions Unit at a
teaching and research hospital in southern India. The secondary purpose of this study was to
identify sociodemographic and behavioral correlates of infection. Overall, information about
the prevalence and correlates of STIs can help policy makers, health care providers, and
researchers to allocate resources to those most in need, and improve understanding of the
possible determinants of STIs in this population.
2. Methods
2.1. Setting
The study was conducted at the 60-bed inpatient DeAddictions Unit of the National Institute
of Mental Health and Neuro Sciences (NIMHANS) in Bangalore, India. NIMHANS is a 600-
bed state psychiatric hospital that serves patients from urban, semi-urban, and rural areas,
particularly from southern India. Patients admitted to the inpatient DeAddictions Unit were
eligible to participate if they were: (a) at least 18 years of age, (b) diagnosed with a substance
use disorder, (c) judged to be able to complete the assessment by clinical and research staff,
(d) not acutely psychotic or otherwise unable to participate meaningfully in the study, and (e)
able to provide informed consent.
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2.2. Procedures
All procedures and materials for this cross-sectional study were reviewed and approved by the
Institutional Review Boards of the NIMHANS and Syracuse University, and by the Indian
Council of Medical Research.
2.2.1. Recruitment. Consecutive admissions to the DeAddictions Unit from April to October,
2001 were reviewed with the clinical team to determine their eligibility, and to be certain that
each person was clinically stable and able to participate meaningfully in the research. The
research staff then approached all eligible patients to explain the study, answer questions that
the patient might have, and invite the patient to participate. (All research staff were physicians
with an interest in substance abuse treatment, psychiatry, public health, and/or HIV/AIDS, who
had received training from the investigators prior to working with patients.) Confidentiality
was emphasized with assurances that information would be shared with the treating team only
with consent from the individual. Patients who were interested in participating provided
informed consent.
2.2.2. Interview. Interviews were conducted by well-trained and supervised medical
professionals who (a) took the time to establish rapport with patients, (b) provided reassurances
regarding confidentiality before conducting the interview, and (c) used the language most
comfortable for the patient. These strategies were designed to ease the cognitive burden on the
patients, to facilitate candid reporting, to afford greater cultural sensitivity, to avoid potential
problems associated with patient endurance, and to avoid misunderstandings associated with
language or literacy concerns. The interviews began with an assessment of demographic
characteristics, and then proceeded to questions regarding substance use and sexual behavior.
We used three standardized measures, and all patient responses were recorded by the
Interviewer on a standardized booklet.
First, to assess alcohol use, we employed the Alcohol Use Disorders Identification Test
(Saunders et al., 1993). The AUDIT, a 10 item screening measure yields scores that range from
0-40, identifies drinkers at risk for alcohol abuse and dependence. The AUDIT was constructed
for use in developing countries (Saunders et al., 1993), and has been found to be reliable and
valid in psychiatric settings throughout the world (Maisto et al., 2000), including India (Carey
et al., 2003a).
Second, to assess drug use, we used the short version of Drug Abuse Screening Test (Skinner,
1982), which identifies drug-use related problems in the previous year. The DAST is reliable
and valid in both clinical and non-clinical settings (Maisto et al., 2000). Research conducted
with Indian participants corroborates the unidimensional structure, internal consistency, and
validity of the DAST (Carey et al., 2003a). In addition, patients were asked if they smoked
commercially-prepared cigarettes and/or beedis, and if they chewed tobacco and/or betel nut.
Third, to assess sexual risk behavior, we used the HIV-Risk Screening Instrument (HRSI)
(Gerbert et al., 1998). Ten items assess sexual activity (e.g., “Have you had anal sex — a man
puts his penis into the anus of another person — with any of your sexual partners”), drug use
risk behavior (e.g., “Have you ever injected street drugs, steroids, or vitamins with a needle”),
number of sexual partners (e.g., “Have you had two or more sexual partners”), and other risk
behaviors (e.g., “Have you ever had sex with someone so that they [sic] would give you money
or drugs?”) that discriminate between low-and high-risk groups for contracting HIV.
Modifications (e.g., providing definitions of some words, such as anal sex and steroids) were
made to make the HRSI appropriate to the Indian context (Carey et al., 2003b). A score of zero
reflects low risk, whereas a score of one or more reflects higher risk for HIV infection. To
allow comparisons with previous research, we assessed behavior during the past year as well
Drug Alcohol Depend. Author manuscript; available in PMC 2006 April 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Carey et al. Page 4 of 13
as 10-year risk behavior. The interviewer also asked questions regarding four STI-related
symptoms (i.e., genital discharge, pain while urinating, genital sores, genital swelling) in the
past year.
2.2.3. Specimen collection. When the interview was completed, blood samples were collected
by a trained phlebotomist. The blood specimen involved 5 ml of blood in a plain vial collected
without any anticoagulant. The clotted blood samples were centrifuged at 1000 xg for 20 min
and the serum separated and stored in aliquots at -20° C until laboratory tests were completed.
2.2.4. Laboratory testing. All laboratory tests followed standard procedures. Thus, for HIV 1
and 2, we used a commercial ELISA kit (Bicohem, Canada). Reactive samples were subjected
to a confirmatory Western Blot test (Immunetics, USA). For syphilis, we used a commercial
particle agglutination test kit (Serodia, Japan) to detect antibodies to Treponema pallidum.
Specimens showing agglutination in the confirmatory test were considered positive indicating
current or past infection with this organism. For Chlamydia, we employed a commercial ELISA
kit (Novum Diagnostica) for the detection of IgG antibodies to Chlamydia. A sample having
an Optical Density (OD) value 10% over that obtained with a cut-off sample was considered
positive indicating current or past infection. For Hepatitis B, we used a commercial ELISA kit
(DiaSorin, Italy) for the detection of surface antigen in serum samples. Samples giving OD
values within 10% of cut-off value were considered positive.
2.2.5. STI treatment and care. Patients who tested positive for any STI were informed of their
infection, counseled, and referred for continued medical and psychosocial care.
2.2.6. Data management and analyses. Data were double entered, and compared for accuracy.
Discrepancies were compared against the raw data to correct clerical errors. To provide
prevalence estimates, simple percentages were calculated. Initially, we intended to implement
a series of logistic regression models to identify correlates of STIs. However, due to the low
base rates of positive test results in these data, logistic regression could not be implemented.
In particular, estimation of logistic regression models with outcome variables that have low
base rates yields estimated regression coefficients that tend toward infinity (with equally large
standard errors and confidence intervals), particularly when specific covariates/categories have
no variability in the outcome variable (Hosmer and Lemeshow, 2000). Therefore, bivariate
analyses were used to provide estimates of the degree of correlation between each STI and
demographic, psychiatric, substance use, and behavioral risk variables. Furthermore, due to
the low predicted cell sizes, we used Fisher's Exact tests to compare infected and not-infected
groups. Initial gender comparisons were made; however, due to the small number of women
included in the study, subsequent comparisons were made using data provided by males only.
3. Results
During the study period, there were 493 admissions to the DeAddictions Unit. Of these patients,
50 were discharged early; 40 could not be interviewed because they left the hospital against
medical advice; 38 were unable to comprehend and respond to the interview because of an
acute psychiatric problem; and 4 were not eligible for reasons such as readmission, age older
than 65 years, language problems, or need for immediate transfer to another medical units.
Thus, 361 patients with problems primarily related to substance use were available and
consented to participate in the study.
Patients (98% male) mean age was 36.7 years (SD = 9.2). Patients preferred language was 37%
Kannada, 18% Telugu, 23% Tamil, 3% Hindi, and 19% others. Religious affiliation was 82%
Hindu, 6% Muslim, 10% Christian, and 2% other. Most had some formal education with 36%
having completed primary level education, 30% high school, 10% pre-university, and 14%
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university; only 59% reported earning wages from a job. Among all patients, 252 (70%) were
married and living with their spouse, 25 (7%) were married but living apart, and 84 (23%) were
not married, divorced, or widowed. Approximately 66% lived in an urban area, 19% in a rural
area, and 15% in a semi-urban area. Forty-five percent lived in their own home, with the
remaining patients living in their family home (38%), the home of another person (14%), an
institution or a halfway home (less than 1%) or were homeless (1.1%).
Most patients (n = 319; 88%) were diagnosed with an alcohol use disorder, 20 (6%) had an
opioid use disorder, 6 (2%) had a cannabinoid use disorder, 1 (0.3%) had a sedative/hypnotic
use disorder, and 15 (4%) had a multiple substance use disorder. Only seven patients injected
drugs in the past year, and eleven reported injection drug use during their lifetime. A minority
(n =34; 9%) were dually-diagnosed with a psychiatric disorder. The duration of illness was <
6 months in 43 (12%) cases, 6 to 12 months in 19 (5%) cases, 1 to 5 years in 109 (30%) cases,
and more than 5 years in 190 (53%) cases. The mean number of previous psychiatric admissions
was 0.6 (SD = 1.3).
3.1. HIV
HIV data were missing for 5 participants. Four of the 356 patients tested were infected with
HIV (1.1%;95% CI = 0.3, 2.9). Patients testing positive included only men with a mean age
of 29.5 years (SD = 5.1), all of whom were diagnosed with only an alcohol use disorder.
Bivariate comparisons contrasted patients diagnosed with HIV and those who tested negative.
Comparisons for demographic, psychiatric, and substance use variables are presented in Table
1. No women tested positive for HIV, but this gender comparison was not statistically
significant. Among men, none of these variables were significantly correlated with HIV status.
Bivariate comparisons for behavioral risk variables and self-reported STI data are presented
in Table 2. Among these variables, only having paid for sex in the past 10 years was
significantly correlated with HIV status (Fisher's p < .01), with men who paid for sex showing
significantly higher rates of HIV positive status compared to men who did not pay for sex.
3.2. Chlamydia
Chlamydia test data were missing for 11 participants. Thirty-six of the 350 patients tested
positive for lifetime exposure to Chlamydia (10.3%; 95% CI = 7.3, 14.0). Patients testing
positive included men (n = 33) and women (n = 3) with a mean age of 37.0 years (SD = 8.9).
The diagnostic breakdown for those who tested positive was: alcohol use disorder (n = 32),
cannabinoids use disorder (n = 1), and multiple substance use disorder depression (n = 3). Two
patients were also diagnosed with a psychiatric disorder.
Bivariate comparisons contrasted patients diagnosed with Chlamydia and those who tested
negative. Bivariate comparisons for demographic, psychiatric, and substance use variables
are presented in Table 1. The rate of infection among men and women was not significantly
different. Among men, none of these variables were significantly correlated with a positive
Chlamydia test result. Bivariate comparisons for behavioral risk variables and self-reported
STI data are presented in Table 2. None of these variables was correlated with a positive
Chlamydia test.
3.3. Syphilis
TPPA test data were missing for 5 participants. Forty-six of the 356 patients tested positive for
lifetime exposure to Syphilis (12.9%; 95% CI = 9.6, 16.9). Patients testing positive included
men (n = 45) and women (n = 1) with a mean age of 37.7 years (SD = 8.5). The diagnostic
breakdown for those who tested positive was: alcohol use disorder (n = 45), opioid use disorder
(n = 1). Four patients were also diagnosed with a psychiatric disorder.
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Bivariate comparisons contrasted patients diagnosed with Syphilis and those who tested
negative. Bivariate comparisons for demographic, psychiatric, and substance use variables
are presented in Table 1. Infection rates did not differ between men and women. Among men,
marital status (Fisher's p < .01), primary substance use diagnosis (Fisher's p < .01), duration
of illness (Fisher's p < .05), AUDIT score (Fisher's p < .05), and DAST score (Fisher's p < .
01) were all correlated with a positive Syphilis test result. In particular, married men, men
diagnosed with an alcohol use disorder, a significant AUDIT score, and DAST score were all
associated with higher rates of Syphilis infection. Interpretation of duration of illness is more
difficult, with men diagnosed in the past 1-5 years showing lower rates of Syphilis infection
compared to individuals diagnosed for shorter and longer periods of time. Bivariate
comparisons for behavioral risk variables and self-reported STI data are presented in Table 2.
None of these variables was correlated with a positive Syphilis test result.
3.4. Hepatitis B
Hepatitis B test data were missing for 5 participants. Eleven of the 356 patients tested were
positive for Hepatitis B (3.1%; 95% CI = 1.6, 5.5). Patients testing positive included men (n =
10) and women (n = 1) with a mean age of 30.1 years (SD = 7.0). The diagnostic breakdown
for those who tested positive was: alcohol use disorder (n = 8), opioid use disorder (n = 2), and
cannabinoid use disorder (n = 1). One patient was also diagnosed with a psychiatric disorder.
Bivariate comparisons contrasted patients diagnosed with Hepatitis B and those who tested
negative. Bivariate comparisons for demographic, psychiatric, and substance use variables
are presented in Table 1. The rate of infection among men and women was not significantly
different. Among men, none of these variables were significantly correlated with a positive
Hepatitis B test result. Bivariate comparisons for behavioral risk variables and self-reported
STI data are presented in Table 2. Among these variables, only having multiple sexual partners
in the past year was significantly correlated with a positive result (Fisher's p < .01), with men
who reported multiple partners having higher rates of Hepatitis B infection compared to men
with zero or one sexual partner.
3.5. All STIs
Of the 356 patients tested for at least three STIs, 88 were infected with at least one STI (24.7%;
95% CI = 20.3, 29.5); when analyses were restricted to only those patients who provided data
for all four STIs, 88 of the 350 (25.1%; 95% CI = 20.7, 30.0) were infected with at least one
STI. Nine of the 356 patients (2.5%; 95% CI = 1.2, 4.5) were diagnosed with more than one
STI.
Comparisons of patients diagnosed with any STI with those who tested negative revealed
several differences. Bivariate comparisons for demographic, psychiatric, and substance use
variables are presented in Table 1. Any STI was significantly correlated with gender (Fisher's
p < .05), with women being more likely to test positive for at least one STI compared to men.
Remaining comparisons made among men only indicated that AUDIT score (Fisher's p < .05)
and DAST score (Fisher's p < .05) were both correlated with at least one positive test result.
In particular, men with a clinically significant AUDIT score and a clinically non-significant
DAST score were more likely to test positive for at least one STI. Comparisons for behavioral
risk variables and self-reported STI data are presented in Table 2. None of these variables was
correlated with a positive test result.
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4. Discussion
This report provides the first, large-scale investigation of the prevalence of HIV and three other
serious STIs among men and women seeking treatment for a substance abuse disorder at the
eAddictions Unit of the National Institute of Mental Health and Neuro Sciences (NIMHANS)
in Bangalore, India. Strengths of the study include the use of consecutive admissions screening
(avoiding a self-selection bias), biological confirmation of STI status, assessment using
standardized laboratory procedures and clinical measures with known psychometric properties,
special sensitivity to language and culture, and a relatively large and diverse sample; these
strengths enhance confidence in the validity and representativeness of the findings.
Results indicated lifetime seroprevalence rates of 12.9% for syphilis, 10.3% for chlamydia,
3.1% for Hepatitis B, and 1.1% for HIV. Nearly one-quarter of all patients tested positive for
at least one STI. The STI rates observed in this study exceed those found in a recent samples
of patients in substance abuse settings in the U. S. (Liebschutz et al., 2003) and Canada (Poulin
et al., 1999), and also exceed rates found in community samples in India. For example, in a
recent study of the prevalence of anti-Chlamydial antibodies in Tamil Nadu, 2.4% were
determined to be infected (Joyee et al., 2004). The rate of HIV infection (1.1%) also appears
to be higher than rates reported for the general Indian population (i.e., 0.7-0.9%; Solomon et
al., 2004). Such comparisons must be made cautiously, however, due to sampling and other
methodological differences. However, if the estimates obtained with the current sample are
representative, these findings suggest that patients being treated for a substance use disorder
in India are at slightly elevated risk for STIs, including HIV. Ongoing surveillance of HIV and
other STIs in India can help to clarify the nature of the epidemic, and guide policy efforts.
Several explanations can be offered to explain why persons who abuse alcohol and other drugs
may be vulnerable to STIs. For example, alcohol and other drug use impairs judgment, and
may lead to poor decisions regarding sexual behavior. Adults with a substance abuse disorder
often cannot work, and often live in circumstances and environments that are especially risky,
or may need to exchange sex for food, shelter, or safety. Indeed, epidemiological studies
document the increased risk associated with poverty and other forms of social disadvantage
(Farmer, 1999, Berkman and Kawachi, 2000). Drug use can compromise the interpersonal and
social skills needed to negotiate for safer sexual relationships, and may lead to less stable sexual
partnerships, partner concurrency, sexual bartering, and risky sexual behavior, all of which
increase their vulnerability for STIs. Further research on the mechanisms by which alcohol and
drug use may increase risk for STIs is needed.
A secondary purpose of this research was to identify sociodemographic and behavioral
correlates of STIs. Because the sample contained few female patients (n = 9), the study had
limited statistical power to detect gender differences on the individual STIs. However, when
diagnosis with any STI was considered, women were more likely to be infected (56%) than
were men (24%). The higher estimate among women is consistent with data indicating that
women are more biologically vulnerable to STIs (Nicolosi et al., 1994, Padian et al., 1997).
Continued study of the unique risks of women, with larger samples of females with substance
use disorders, is needed.
Overall, however, analyses did not reveal a consistent pattern of patient demographic,
psychiatric, and behavioral characteristics that were associated with having a STI. Although a
few significant associations did emerge (e.g., between duration of illness and syphilis), such
associations did not replicate across STIs; thus, it appears prudent to interpret the inconsistent
pattern of associations as reflecting chance associations, until future research demonstrates a
more consistent pattern. Overall, then, data from this large sample did not identify a profile
based on demographic, psychiatric, or behavioral characteristics that covary with STI risk.
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The results are important, but need to be interpreted cautiously given the limitations of our
research. First, our sample included only a few women. Our sample reflects the much lower
prevalence of substance use problems among women in India, relative to developed countries
(i.e., Indian men are nearly 10 times more likely than Indian women to regularly use
alcohol; Neufeld et al., 2005). However, in this time of rapid cultural change and globalization,
it is possible that rates of substance use among Indian women may increase, and careful
attention to this matter is recommended. Second, our data were collected from a specialized
DeAddictions unit at a large teaching and research hospital. Given the specialized nature of
this institution, these results should be replicated in other setting and parts of the country before
generalization to the larger population of patients seeking treatment for a substance use disorder
is warranted. Third, these data were collected in 2001; given the dynamic nature of the HIV
epidemic, inferences about current prevalence should be made cautiously. Fourth, we did not
test for other STIs, such as herpes simplex virus, human papilloma virus, candida, trichomonas,
chancroid, and non-specific genital inflammations such as bacterial vaginosis. Had we tested
for these infections, it is likely that a higher percentage of study participants would have been
found to be infected with an STI. Fifth, the tests that we did use indicate lifetime exposure;
thus, our methods do not allow us to provide point prevalence estimates for acute exposure to
chlamydia or syphilis. Such estimates are likely to be significantly lower, and should be
addressed in future research. Finally, due to the low base rates of some STIs, it was not possible
to complete multivariate analyses that controlled for the effects of other predictors.
Several recommendations appear justified on the basis of these findings. First, we recommend
that all patients receiving treatment for an alcohol or other drug problem receive a
comprehensive sexual health assessment as a part of standard clinical care. This assessment
should include a detailed sexual history, with attention to signs and symptoms of STIs as well
as risk behavior. Second, we recommend that addictions specialists receive ongoing training
in human sexuality so that they can conduct such assessments, and better assist patients who
have concerns or require special attention. Given the stigma still associated with HIV and other
STIs, such training will help to lower provider-related barriers to optimal care. Third, we
recommend that patients who report a history of multiple partners, exchanging money for sex
or sex for money (or other resource needs), anal sex, injection drug use, and men who have
sex with men be encouraged to undergo voluntary counseling and testing for HIV and other
STIs. We recommend this even in the absence of a presenting sexual concern because STIs are
often asymptomatic. Fourth, given the low prevalence of HIV observed in our sample relative
to other population sub-groups (e.g., commercial sex workers, STI clinic patients) and the finite
resources available for health care, we do not — at this time — recommend universal HIV
testing for patients receiving substance use treatment at settings similar to the one where our
data were collected. This recommendation is similar to that reached for the U.S. (Liebschutz
et al., 2003), and is also consistent with recent cost-effectiveness analyses regarding when such
universal screening is warranted (Paltiel et al., 2005). This recommendation should be revisited
regularly, however, and informed by surveillance of HIV in the general Indian population. We
encourage research that samples from a variety of settings in order to determine STI rates in
the larger population of treatment seekers. HIV in particular is a dynamic epidemic, and
requires continued vigilance to avert a worsening epidemic.
In conclusion, the findings of this study suggest that 25% of patients in treatment for an alcohol
or drug abuse disorder have been infected with a STI in their lifetime. More than 1% were
infected with HIV. Based upon bivariate analyses of patient demographic, psychiatric, or
behavioral characteristics, we did not find a consistent risk pattern or profile associated with
STIs. These findings warrant replication but lead to a set of clinical and public health
recommendations to benefit Indian patients in treatment for a substance abuse disorder.
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Table 1
Bivariate Associations Between STI Infection Rates and Demographic, Psychiatric, and
Substance Use Characteristics
n
a
HIV Chlamydia Syphilis Hepatitis B Any STI
Demographic Variables
Gender
Female 9/9 0 (0.0%) 3 (33.3%) 1 (11.1%) 1 (11.1%) 5 (55.6%)
*
Male 347/341 4 (1.2%) 33 (9.7%) 45 (13.0%) 10 (2.9%) 83 (23.9%)
*
Age
18-28 71/71 3 (4.2%) 6 (8.5%) 5 (7.0%) 4 (5.6%) 16 (22.5%)
29-38 140/135 1 (0.7%) 12 (8.9%) 22 (15.7%) 5 (3.6%) 35 (25.0%)
39-48 100/99 0 (0.0%) 14 (14.1%) 13 (13.0%) 1 (1.0%) 26 (26.0%)
48+ 36/36 0 (0.0%) 1 (2.8%) 5 (13.9%) 0 (0.0%) 6 (16.7%)
Level of Education
No Formal Education 35/34 0 (0.0%) 3 (8.8%) 6 (17.1%) 1 (2.9%) 8 (22.9%)
High School 228/225 4 (1.8%) 22 (9.8%) 34 (14.9%) 6 (2.6%) 61 (26.8%)
College 84/82 0 (0.0%) 8 (9.8%) 5 (6.0%) 3 (3.6%) 14 (16.7%)
Marital Status
Unmarried 105/102 3 (2.9%) 6 (5.9%) 6 (5.7%)
**
5 (4.8%) 18 (17.1%)
Married 242/239 1 (0.4%) 27 (11.3%) 39 (16.1%)** 5 (2.1%) 65 (26.9%)
Living Environment
Rural 119/119 1 (0.8%) 10 (8.4%) 17 (14.3%) 6 (5.0%) 31 (26.1%)
Urban 228/222 3 (1.3%) 23 (10.4%) 28 (12.3%) 4 (1.8%) 52 (22.8%)
Living Situation
Own Home 159/155 1 (0.6%) 13 (8.4%) 20 (12.6%) 2 (1.3%) 33 (20.8%)
Others' Home 188/186 3 (1.6%) 20 (10.8%) 25 (13.3%) 8 (4.3%) 50 (26.6%)
Occupation
Unemployed 60/57 0 (0.0%) 4 (7.0%) 7 (11.7%) 3 (5.0%) 13 (21.7%)
Nonprofessional 172/169 3 (1.7%) 20 (11.8%) 25 (14.5%) 5 (2.9%) 46 (26.7%)
Professional 115/115 1 (0.9%) 9 (7.8%) 13 (11.3%) 2 (1.7%) 24 (20.9%)
Psychiatric Variables
Diagnosis
Alcohol Use Disorder 308/303 4 (1.3%) 30 (9.9%) 45 (14.6%)** 7 (2.3%) 77 (25.0%)
Other Substance Use 39/38 0 (0.0%) 3 (7.9%) 0 (0.0%)
**
3 (7.7%) 6 (15.4%)
Dual Diagnosis
No 314/309 4 (1.3%) 31 (10.0%) 41 (13.1%) 9 (2.9%) 77 (24.5%)
Yes 33/32 0 (0.0%) 2 (6.3%) 4 (12.1%) 1 (3.0%) 6 (18.2%)
Duration of Substance
UseDisorder
< 6 Months 41/41 0 (0.0%) 5 (12.2%) 6 (14.6%)
*
2 (4.9%) 10 (24.4%)
6-12 Months 19/19 0 (0.0%) 2 (10.5%) 3 (15.8%)
*
1 (5.3%) 6 (31.6%)
1-5 Years 106/104 2 (1.9%) 8 (7.7%) 6 (5.7%)
*
3 (2.8%) 19 (17.9%)
> 5 Years 181/177 2 (1.1%) 18 (10.2%) 30 (16.6%)
*
4 (2.2%) 48 (26.5%)
Substance Use Variables
Cigarette Smoking
No 202/200 1 (0.5%) 21 (10.5%) 30 (14.9%) 7 (3.5%) 52 (25.7%)
Yes 145/141 3 (2.1%) 12 (8.5%) 15 (10.3%) 3 (2.1%) 31 (21.4%)
Beedis Smoking
No 136/134 1 (0.7%) 13 (9.7%) 14 (10.3%) 5 (3.7%) 28 (20.6%)
Yes 211/207 3 (1.4%) 20 (9.7%) 31 (14.7%) 5 (2.4%) 55 (26.1%)
Chewing Tobacco
No 264/259 2 (0.8%) 24 (9.3%) 37 (14.0%) 7 (2.7%) 64 (24.3%)
Yes 83/82 2 (2.4%) 9 (11.0%) 8 (9.6%) 3 (3.6%) 19 (22.9%)
Betel nut Use
No 256/254 4 (1.6%) 21 (8.3%) 30 (11.7%) 8 (3.1%) 58 (22.7%)
Yes 91/87 0 (0.0%) 12 (13.8%) 15 (16.5%) 2 (2.2%) 25 (27.5%)
AUDIT Score
< 8 28/28 0 (0.0%) 0 (0.0%) 0 (0.0%)
*
2 (7.1%) 2 (7.1%)
*
8+ 319/313 4 (1.3%) 33 (10.5%) 45 (14.1%)
*
8 (2.5%) 81 (25.4%)
*
DAST Score
< 2 288/285 3 (1.0%) 29 (10.2%) 44 (15.3%)** 8 (2.8%) 75 (26.0%)
*
2+ 59/56 1 (1.7%) 4 (7.1%) 1 (1.7%)
**
2 (3.4%) 8 (13.6%)
*
*
,p < .05
**
,p < .01
***
,p < .001.
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a
All variables — other than gender — include data from males only; thus, results for HIV, Syphilis, Hepatitis B, and Any STI are based on n = 347, and
sample size is represented by the number on the left side of the slash in the column; Chlamydia results are based on n = 341, andsample size is represented
by the number on the right side of the slash in the column. Some variables may not reflect these overall sample sizesdue to missing data.
Drug Alcohol Depend. Author manuscript; available in PMC 2006 April 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Carey et al. Page 13 of 13
Table 2
Bivariate Associations Between STI Infection Rates and Behavioral Risk Variables
n
a
HIV Chlamydia Syphilis Hepatitis B Any STI
Behavioral Risk Variables
Last Sexual Activity
Never 29/29 0 (0.0%) 3 (10.3%) 3 (10.3%) 2 (6.9%) 7 (24.1%)
Past Year 270/266 2 (0.7%) 29 (10.9%) 38 (14.1%) 6 (2.2%) 67 (24.8%)
Last 10 Years 42/40 2 (4.8%) 1 (2.5%) 3 (7.1%) 2 (4.8%) 8 (19.1%)
Lifetime 6/6 0 (0.0%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 1 (16.7%)
Paid for Sex, Past 10 Years
No 282/277 1 (0.4%)
*
26 (9.4%) 38 (13.5%) 7 (2.5%) 65 (23.1%)
Yes 65/64 3 (4.6%)
*
7 (10.9%) 7 (10.8%) 3 (4.6%) 18 (27.7%)
Paid for Sex, Past Year
No 330/324 3 (0.9%) 29 (9.0%) 44 (13.3%) 8 (2.4%) 77 (23.3%)
Yes 17/17 1 (5.9%) 4 (23.5%) 1 (5.9%) 2 (11.8%) 6 (35.3%)
Been Paid for Sex, Lifetime
No 321/315 4 (1.3%) 32 (10.2%) 41 (12.8%) 10 (3.1%) 78 (24.3%)
Yes 20/20 0 (0.0%) 1 (5.0%) 3 (15.0%) 0 (0.0%) 4 (20.0%)
Been Paid for Sex, Past Year
No 345/339 4 (1.2%) 32 (9.4%) 45 (13.0%) 10 (2.9%) 82 (23.8%)
Yes 2/2 0 (0.0%) 1 (50.0%) 0 (0.0%) 0 (0.0%) 1 (50.0%)
Multiple Partners, Past 10
Years
No 239/236 1 (0.4%) 24 (10.2%) 32 (13.4%) 5 (2.1%) 56 (23.4%)
Yes 108/105 3 (2.8%) 9 (8.6%) 13 (12.0%) 5 (4.6%) 27 (25.0%)
Multiple Partners, Past Year
No 323/318 3 (0.9%) 28 (8.8%) 44 (13.6%) 7 (2.2%)
*
75 (23.2%)
Yes 24/23 1 (4.2%) 5 (21.7%) 1 (4.2%) 3 (12.5%)
*
8 (33.3%)
Men who have sex with men,
Past 10 Years
No 340/334 4 (1.2%) 32 (9.6%) 45 (13.2%) 10 (2.9%) 82 (24.1%)
Yes 6/6 0 (0.0%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 1 (16.7%)
Men who have sex with men,
Past Year
No 343/337 4 (1.2%) 32 (9.5%) 45 (13.1%) 10 (2.9%) 82 (23.9%)
Yes 3/3 0 (0.0%) 1 (33.3%) 0 (0.0%) 0 (0.0%) 1 (33.3%)
Anal Sex, Past 10 Years
No 324/318 4 (1.2%) 31 (9.8%) 44 (13.6%) 9 (2.8%) 79 (24.4%)
Yes 23/23 0 (0.0%) 2 (8.7%) 1 (4.4%) 1 (4.4%) 4 (17.4%)
Anal Sex, Past Year
No 335/329 4 (1.2%) 31 (9.4%) 45 (13.4%) 9 (2.7%) 80 (23.9%)
Yes 12/12 0 (0.0%) 2 (16.7%) 0 (0.0%) 1 (8.3%) 3 (25.0%)
Self-reported STI Variables
STI Symptoms Reported
No 335/330 3 (0.9%) 32 (9.7%) 44 (13.1%) 9 (2.7%) 80 (23.9%)
Yes 12/11 1 (8.3%) 1 (9.1%) 1 (8.3%) 1 (8.3%) 3 (25.0%)
STI Lifetime
No 308/305 3 (1.0%) 32 (10.5%) 36 (11.7%) 9 (2.9%) 72 (23.4%)
Yes 33/30 1 (3.0%) 1 (3.3%) 8 (24.2%) 1 (3.0%) 10 (30.3%)
STI Past Year
No 342/336 3 (0.9%) 33 (9.8%) 45 (13.2%) 10 (2.9%) 82 (24.0%)
Yes 5/5 1 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (20.0%)
*
, p < .05
**
, p < .01
***
, p < .001.
a
All variables only include male participants. Results for HIV, Syphilis, Hepatitis B, and Any STI are based on n = 347, and sample sizeis represented
by the number on the left side of the slash in the column; Chlamydia results are based on n = 341, and sample size is represented bythe number on the
right side of the slash in the column. Some variables may not reflect these overall sample sizes due to missing data.
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